Diabetes Management

Summary New research suggests GLP-1 receptor agonists, commonly used to treat type 2 diabetes, may significantly reduce the risk of certain blood cancers like leukemia and lymphoma in these patients. This potential benefit adds to […]

Summary Tandem Diabetes Care receives FDA approval for its Control-IQ+ automated insulin delivery system for Type 2 diabetes. This approval marks a significant advancement in diabetes management, offering an alternative to multiple daily injections. The […]

Summary This article explores the groundbreaking research on automated insulin delivery (AID) systems for older adults with type 1 diabetes. Studies show these systems are safe, effective, and improve glucose control while reducing hypoglycemia risks, […]

Summary This article explores a study published in the Journal of the American Heart Association which demonstrated that limiting TV time to one hour or less per day may reduce heart disease risk for individuals […]

Summary A temporary gut liner shows promise in aiding weight loss and lowering A1c levels, even two years after removal. This non-surgical device offers a less invasive alternative to traditional weight-loss procedures. The gut liner […]

Summary Researchers unveil promising results from a phase 1 trial of a novel oral weight loss drug, amycretin. The drug combines amylin and a GLP-1 receptor agonist, potentially offering a more convenient and effective approach […]

Summary The FDA issued a warning letter to Dexcom, a leading continuous glucose monitor (CGM) manufacturer, after inspections revealed quality management issues. While Dexcom assures the public this won’t impact production or sales, the situation […]

Summary This article explores five common medications known to elevate blood glucose levels, a crucial consideration for individuals managing diabetes. We delve into how these medications impact blood sugar, potential risks, and steps to mitigate […]

Summary GLP-1 drugs, while effective for diabetes and weight loss, remain expensive even for insured patients. Many insurance plans require patients to share the cost, and some plans don’t cover GLP-1 drugs for weight loss. […]

Summary The FDA’s approval of over-the-counter continuous glucose monitors (CGMs) marks a significant advancement in diabetes management, expanding access to crucial health data without a prescription. These devices offer real-time glucose insights, empowering individuals to […]